Entrada Therapeutics appoints Maha Radhakrishnan, M.D. to board effective June 1, 2025

Entrada Therapeutics, Inc.

Maha Radhakrishnan, M.D. appointed as Class III director; board expanded from 6 to 7 members.
Also appointed to Audit Committee, replacing Kush Parmar, M.D., Ph.D.; Parmar remains chairman.
Current Executive Partner at Sofinnova Investments; former CMO of Biogen (2019-2024).
Initial equity award: option to purchase 38,000 shares vesting over 3 years; annual cash fees of $40,000 + $9,000 Audit Committee retainer.
Appointment takes effect June 1, 2025; serves until 2027 annual meeting.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Maha Radhakrishnan

Class III director

TRDA · Entrada Therapeutics, Inc.

Effective: 2025-06-01
Filed: Jun 03, 2025 23:59 UTC

On May 30, 2025, the Board of Directors (the “Board”) of Entrada Therapeutics, Inc. (the “Company”) expanded the size of the Board from six to seven directors and appointed Maha Radhakrishnan, M.D. to the Board as a Class III director, to serve until the Company’s annual meeting of stockholders to be held in 2027 or until her successor is duly elected and qualified, in each case effective as of June 1, 2025.

Source: SEC EDGAR

accession 0001689375-25-000027

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.